---
document_datetime: 2025-12-29 09:00:04
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/teizeild.html
document_name: teizeild.html
version: success
processing_time: 0.2779448
conversion_datetime: 2025-12-30 00:09:26.515693
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Teizeild

[RSS](/en/individual-human-medicine.xml/270331)

##### Opinion

EMA has issued an opinion on this medicine

teplizumab Medicine Human Opinion

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [News on Teizeild](#news-on)

## Overview

On 13 November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Teizeild, intended for the treatment of type 1 diabetes (T1D). The applicant for this medicinal product is Sanofi Winthrop Industrie.

Teizeild is a PRIME medicine. This scheme optimises development and accelerates the evaluation of medicines that fulfil an unmet medical need, helping them to reach patients sooner.

Teizeild will be available as a 1 mg/ml concentrate for solution for infusion. The active substance of Teizeild is teplizumab, a diabetes drug (ATC code: A10XX01). Teplizumab is a humanised immunoglobulin G1 monoclonal antibody that binds to the CD3Îµ chain of the T cell receptor (TCR)-complex on human T lymphocytes. The mechanism of action of teplizumab is not fully understood, but it is thought to involve partial agonistic signalling and deactivation of pancreatic beta-cell autoreactive T lymphocytes.

Teizeild preserves beta cell function and delays the onset of stage 3 T1D. The main evidence for the effectiveness of Teizeild was based on a multicentre, double-blind, randomised, placebo-controlled study (TN-10) in people with stage 2 T1D at high risk for progressing to stage 3 T1D. The study showed that the median time to progression to stage 3 T1D was 49.5 months in the Teizeild group, compared with 24.9 months in the placebo group.

The most frequently reported adverse reactions were lymphopenia, leukopenia, neutropenia and rash. The most frequent serious adverse reaction was cytokine release syndrome.

The full indication is:

Teizeild is indicated to delay the onset of stage 3 type 1 diabetes (T1D) in adult and paediatric patients 8 years of age and older with stage 2 T1D.

Teizeild should be administered by a healthcare professional with access to appropriate medical support to manage potential severe adverse reactions.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorisation has been granted by the European Commission.

CHMP summary of positive opinion for Teizeild

Adopted

Reference Number: EMADOC-1829012207-34306

English (EN) (165.29 KB - PDF)

**First published:** 14/11/2025

**Last updated:** 20/11/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-teizeild_en.pdf)

## Product details

Name of medicine Teizeild Active substance teplizumab International non-proprietary name (INN) or common name teplizumab Therapeutic area (MeSH) Diabetes Mellitus, Type 1 Anatomical therapeutic chemical (ATC) code A10XX01 EMA product number EMEA/H/C/005496

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation applicant Sanofi Winthrop Industrie Opinion adopted 13/11/2025 Opinion status Positive

#### News on Teizeild

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025) 14/11/2025

[First-in-class treatment to delay onset of type 1 diabetes](/en/news/first-class-treatment-delay-onset-type-1-diabetes) 14/11/2025

**This page was last updated on** 20/11/2025

## Share this page

[Back to top](#main-content)